TY - JOUR T1 - Early discharge after transfemoral transcatheter aortic valve implantation JF - Heart JO - Heart SP - 1485 LP - 1490 DO - 10.1136/heartjnl-2014-307351 VL - 101 IS - 18 AU - Marco Barbanti AU - Piera Capranzano AU - Yohei Ohno AU - Guilherme F Attizzani AU - Simona Gulino AU - Sebastiano Immè AU - Stefano Cannata AU - Patrizia Aruta AU - Vera Bottari AU - Martina Patanè AU - Claudia Tamburino AU - Daniele Di Stefano AU - Wanda Deste AU - Daniela Giannazzo AU - Giuseppe Gargiulo AU - Giuseppe Caruso AU - Carmelo Sgroi AU - Denise Todaro AU - Emanuela di Simone AU - Davide Capodanno AU - Corrado Tamburino Y1 - 2015/09/15 UR - http://heart.bmj.com/content/101/18/1485.abstract N2 - Background The aim of this study was to assess the feasibility and the safety of early discharge (within 72 h) after transfemoral transcatheter aortic valve implantation (TAVI) and to identify baseline features and/or peri-procedural variables, which may affect post-TAVI length-of-stay (LoS) duration.Methods and results Patients discharged within 72 h of TAVI (early discharge group) were compared with consecutive patients discharged after 3 days (late discharge group). Propensity-matched cohorts of patients with a 2:1 ratio were created to better control confounding bias. Among 465 patients, 107 (23.0%) were discharged within 3 days of the procedure. Multivariable regression analysis of unmatched patients demonstrated that baseline New York Heart Association (NYHA) class IV (OR: 0.22, 95% CI 0.05 to 0.96; p=0.045) and any bleeding (OR: 0.31, 95% CI 0.74 to 0.92; p=0.031) were less likely to be associated with early discharge after TAVI. Conversely, the year of procedure (OR: 1.66, 95% CI 1.25 to 2.20; p<0.001) and the presence of a permanent pacemaker (PPM) before TAVI (OR: 2.80, 95% CI 1.36 to 5.75; p=0.005) were associated with a higher probability of early discharge. In matched populations, patients in the early discharge group reported lower incidence of in-hospital bleeding (7.9% vs 19.4%, p=0.014), major vascular complications (2.3% vs 9.1%, p=0.038) and PPM implantation (7.9% vs18.5%, p=0.021), whereas after discharge, at 30-day, no significant differences were reported between groups in terms of death (2.2% vs 1.7%, p=0.540), bleeding (0.0% vs 1.1%, p=0.444), PPM implantation (1.1% vs 0.0%, p=0.333) and re-hospitalisation (1.1% vs 1.1%, p=1.000).Conclusions Early discharge (within 72 h) after transfemoral TAVI is feasible and does not seem to jeopardise the early safety of the procedure, when performed in a subset of patients selected by clinical judgement. Patients undergoing TAVI in unstable haemodynamic compensation and patients experiencing bleeding after the procedure demonstrated to be poorly suitable to this approach, whereas increasing experience in post-TAVI management was associated with a reduction of LoS. ER -